FIP1L1- platelet-derived growth factor receptor A -positive chronic eosinophilic leukemia showing dramatic response to imatinib

Introduction

Eosinophilia associated with FIP1L1- platelet-derived growth factor receptor A (PDGFRA) rearrangement is one of a subgroup of chronic eosinophilic leukemia, The 2008 World Health Organization classification of tumors of hematopoietic and lymphoid tissues established a new category for myeloid and lymphoid neoplasms with eosinophilia and abnormalities in PDGFRA, platelet-derived growth factor receptor Beta (PDGFRB) or Fibroblast growth factor receptor 1. The number of reported cases is limited worldwide, with limited data on the best modality of treatment of such disease.

Patient concerns

A 48-year-old male patient with recurrent visits to the hospital presenting with multiple vague symptoms but found to have persistent marked eosinophilia.

Diagnosis

The patient was diagnosed as a case of Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA

Interventions

The patient was started on Tyrosine kinase inhibitor (Imatinib) 100 mg daily.

Outcomes

The patient eosinophilia has improved markedly, and the patient's eosinophils levels dropped to normal levels within 3 weeks period.

Conclusion

This case indicates that in the era of Tyrosine Kinase inhibitors such as imatinib, the prognosis of Eosinophilia associated with FIP1L1-PDGFRA rearrangement has significantly improved And Prompt treatment with imatinib can lead to complete hematological response and resolution of any organ damage involved with this disease.

Other Information

Published in: Medicine: Case Reports and Study Protocols
License: http://creativecommons.org/licenses/by/4.0
See article on publisher's website: https://dx.doi.org/10.1097/md9.0000000000000019